A5063305528- Renal Diseases and Glomerulopathies
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Autoimmune Bullous Skin Diseases
- Renal and Vascular Pathologies
- Chronic Kidney Disease and Diabetes
- Genetic and Kidney Cyst Diseases
- Fungal Infections and Studies
- Diabetes Treatment and Management
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Antifungal resistance and susceptibility
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Tuberous Sclerosis Complex Research
- Nail Diseases and Treatments
- Renal and related cancers
- MRI in cancer diagnosis
- Cell Adhesion Molecules Research
- Systemic Lupus Erythematosus Research
- Platelet Disorders and Treatments
- Systemic Sclerosis and Related Diseases
- Kidney Stones and Urolithiasis Treatments
- Gastric Cancer Management and Outcomes
Cooper Medical School of Rowan University
2023-2025
San Francisco Foundation
2025
Cooper University Health Care
2023-2024
Cooper University Hospital
2024
University of Pennsylvania
2020-2022
Systemic anticancer treatment (SAT) for metastatic renal cell carcinoma (mRCC) is associated with a variety of adverse events including hemorrhagic disorders and infections. A substantial number patients mRCC develop chronic kidney disease, which can progress to end-stage disease (ESKD) subsequently require replacement therapy, hemodialysis (HD). It currently not clear how often ESKD who are treated SAT life-threatening bleeding
The majority of patients with metastatic renal cancer (mRC) experience reduced mass (RRM) prior to starting systemic anticancer treatment (SAT) due the local burden primary tumor and/or treatment. Patients who have undergone for carcinoma are at increased risk acute kidney injury (AKI) and progression chronic disease. A percutaneous biopsy (PRB), which is relatively contraindicated in a solitary (SK), serves as reference method assessing toxicity.
Delayed-release (DR) budesonide received expedited approval from the US Food and Drug Administration (FDA) as a treatment for reducing proteinuria in individuals with primary IgA nephropathy (IgAN) who are at significant risk of disease progression. The was based on clinical trials primarily involving patients an estimated glomerular filtration rate (eGFR) greater than 30 mL/min/1.73 m 2 . However, efficacy DR kidney function decline, especially eGFR less 1 g/d, remains unclear. We report...
Bevacizumab is an anti-angiogenic monoclonal antibody against vascular endothelial growth factor (VEGF) and has multiple indications with known renal adverse effects, notably proteinuria, acute kidney injury (AKI). There insufficient knowledge about the long-term outcomes of its effects. In this retrospective study, we reviewed clinical course all patients who received bevacizumab developed therapy associated AKI, chronic disease (CKD), or proteinuria. Among 1,506 bevacizumab, events...
Srinivasan, Vinay; Ahmad, Sarah M.; Aggarwal, Sandeep; Wahba, Ihab Huan, Yonghong Author Information